SCHEMBL14823740

SCHEMBL14823740

CC(C)(C)OC(=O)N1CCC(F)(/C=C/C#N)CC1

nearest known ligand 0.42

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CTSK P43235 1/20 0.38
GPR119 Q8TDV5 2/20 0.38
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
KMT2A Q03164 1/20 0.37
JAK2 O60674 4/20 0.37
JAK1 P23458 4/20 0.37
HPGD P15428 1/20 0.37
EPHX2 P34913 1/20 0.36
DPP4 P27487 1/20 0.36
RECQL P46063 1/20 0.35
EPHX1 P07099 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15983890 1.00 USP2 (0.42) USP2SMN1; SMN2CTSKGPR119MEN1
SCHEMBL845036 0.92 USP2 (0.37) USP2SMN1; SMN2CTSKGPR119MEN1
SCHEMBL3761873 0.92 USP2 (0.37) USP2SMN1; SMN2CTSKGPR119MEN1
SCHEMBL3965735 0.84 USP2 (0.43) USP2SMN1; SMN2CTSKGPR119MEN1
SCHEMBL3965738 0.84 USP2 (0.43) USP2SMN1; SMN2CTSKGPR119MEN1
SCHEMBL19191216 0.83 MEN1 (0.40) USP2SMN1; SMN2CTSKGPR119MEN1
SCHEMBL2887782 0.79 USP2 (0.49) USP2SMN1; SMN2CTSKGPR119MEN1
SCHEMBL1474878 0.79 USP2 (0.49) USP2SMN1; SMN2GPR119MEN1KMT2A
SCHEMBL26636746 0.78 SMN1; SMN2 (0.40) USP2SMN1; SMN2GPR119MEN1ALDH1A1
SCHEMBL5887725 0.77 EPHX1 (0.44) USP2SMN1; SMN2CTSKGPR119MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2758051-B1 CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS MERCK SHARP & DOHME (US) 2018-04-11 EP disclosed
EP-2758377-B1 CYCLOALKYLNITRILE PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS MERCK SHARP & DOHME (US) 2017-08-02 EP disclosed
US-9493441-B2 Acyclic cyanoethylpyrazoles as janus kinase inhibitors MERCK SHARP & DOHME CORP. (US) 2016-11-15 US disclosed
US-9493441-B2 Acyclic cyanoethylpyrazoles as janus kinase inhibitors MERCK SHARP & DOHME CORP. (US) 2016-11-15 US disclosed
EP-2758050-B1 ACYCLIC CYANOETHYLPYRAZOLES AS JANUS KINASE INHIBITORS MERCK SHARP & DOHME (US) 2016-08-31 EP disclosed
US-9328099-B2 Cyanomethylpyrazole carboxamides as janus kinase inhibitors MERCK SHARP & DOHME CORP. (US) 2016-05-03 US disclosed
US-9328099-B2 Cyanomethylpyrazole carboxamides as janus kinase inhibitors MERCK SHARP & DOHME CORP. (US) 2016-05-03 US disclosed
US-8962608-B2 Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors MERCK SHARP & DOHME CORP. (US) 2015-02-24 US disclosed
US-20140243309-A1 CYCLOALKYLNITRILE PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS MERCK SHARP & DOHME LLC 2014-08-28 US disclosed
US-20140228348-A1 CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS MERCK SHARP & DOHME LLC 2014-08-14 US disclosed
US-20140228348-A1 CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS MERCK SHARP & DOHME LLC 2014-08-14 US disclosed
US-20140228358-A1 ACYCLIC CYANOETHYLPYRAZOLES AS JANUS KINASE INHIBITORS MERCK SHARP & DOHME LLC 2014-08-14 US disclosed
US-20140228358-A1 ACYCLIC CYANOETHYLPYRAZOLES AS JANUS KINASE INHIBITORS MERCK SHARP & DOHME LLC 2014-08-14 US disclosed
WO-2013043962-A1 CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2013-03-28 WO disclosed
WO-2013043964-A1 ACYCLIC CYANOETHYLPYRAZOLES AS JANUS KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2013-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140228358-A1 ACYCLIC CYANOETHYLPYRAZOLES AS JANUS KINASE INHIBITORS JAK1, JAK2, JAK3 USP2 2026/4885SMN1; SMN2 4831/4885CTSK 971/4885
US-20140243309-A1 CYCLOALKYLNITRILE PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS JAK1, JAK2, JAK3 USP2 1686/4885SMN1; SMN2 4868/4885CTSK 446/4885
US-20140228348-A1 CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS JAK1, JAK2, JAK3 USP2 1584/4885SMN1; SMN2 4782/4885CTSK 841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.